Based on these data, clinical trials were initiated that demonstrated a significant impact of CDK4/6 inhibitors on the progression of metastatic ER+/HER2- breast cancer in combination with endocrine therapy [12, 27]. This evidence concerns the gene ERBB2 and breast cancer.